PEMBROLIZUMAB
pembrolizumab 100 mg/4 mL injection, 4 mL vial
PEMBROLIZUMAB (11352L)
11352L
Manner of administration:Injection
Restriction (Streamlined authority code: 13726)
Indication: Relapsed or Refractory Hodgkin lymphoma
Treatment phase: Initial treatment
Restriction (Streamlined authority code: 13741)
Indication: Relapsed or Refractory Hodgkin lymphoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 400 mg | # of repeats: 6 | DPMA: $14,870.58 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Keytruda
(pembrolizumab 100 mg/4 mL injection, 4 mL vial)
|
||||
